Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Presence of RET/PTC rearrangement significantly correlated with gender, elevated TSH levels and lymph node metastasis.
|
30467698 |
2020 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The univariate analysis showed that age (P = .008), gender (P = .016), smoking history (P = .010), lymph node metastasis (P = .003), and three driver genes, positive epidermal growth factor receptor (EGFR) mutation (P = .001), positive anaplastic lymphoma kinase (ALK) gene fusion (P = .021), and positive rearranged during transfection (RET) gene fusion (P = .003), were the factors influencing the incidence of brain metastasis.
|
31769228 |
2020 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RET mutation was related to cervical lymph node metastasis in patients with MTC, especially the mutation in Exon 11&13.
|
31494787 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After analyzing the RNA-Seq data of PTC patients from the Cancer Genomic Atlas, 497 differentially expressed PTC genes were found to be associated with HT, of which protein tyrosine phosphatase receptor type C (PTPRC), KIT, and COL1A1 were associated with tumor size and lymph node metastasis (p < 0.05).
|
31686862 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk to develop lymph node metastases was eight times higher in presence of RET rearrangements (p = 0.010).
|
30472213 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is good evidence that somatic RET mutations predict higher rates of lymph node metastasis and persistent disease, and worse survival.
|
31301229 |
2019 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, several clinicopathological factors such as age ≥45 years, VI, ETE, and LNM were shown to be significant risk factors for DM in both PTC and FTC subgroups.
|
28913696 |
2018 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
The multifocality rate of PTC was 35.1% and mPTC were shown to have larger primary tumor diameter, higher rate of lymph node metastasis and less number of accompanying non-cancerous lesions than single PTC in one or both gender groups.
|
28315434 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparing the cytological or, when performed, histological diagnoses with the results of FNAB-Tg, we found that in 24 cases of lymph node metastases from PTC (19 lymph nodes from patients at the first diagnoses and 5 lymph nodes from PTC patients in follow up) the mean level of Thyroglobulin was 1840.11 ng/ml; range: <0,2 to 11440 ng/ml.
|
28558632 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decreased TDR was associated with capsular invasion, ETE and LNM in patients with multifocal PTMC and PTC.
|
28109462 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An activating M918T RET (c.2753T>C) somatic mutation was identified in a lymph node metastasis.
|
28068878 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
Biomarker
|
disease |
BEFREE |
ETE = extrathyroidal extension LNM = lymph node metastasis PTC = papillary thyroid carcinoma PTMC = papillary thyroid microcarcinoma RAI = radioactive iodine TNM = tumor, node, metastasis TTD = total tumor diameter.
|
28156153 |
2017 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, in PTMC patients with EI and/or LNM and/or positive BRAF (high-risk PTMC patients), the prevalence of extrathyroidal invasion, Hashimoto's disease, lymph node metastasis, tumor TNM stage, PEDF positive protein expression, the rate of recurrent disease, and the mRNA expression of anti-angiogenic factors was almost as high as in patients with larger PTC, but with no significant difference.
|
27936049 |
2016 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One asymptomatic carrier had de novo codon 918 mutation (MEN2B) and showed bilateral microcarcinoma with lymph node metastasis at presentation and progressive disease on follow-up.
|
26033033 |
2015 |
Secondary malignant neoplasm of lymph node
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Positive associations were found between levels of miR-146a expression in PTC tissues and gender (female), cervical lymph node metastasis, multifocality, extra tyroidal invasion and advanced clinical TNM stages (III and IV).
|
25524940 |
2015 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide copy number analysis in a family with p.G533C RET mutation and medullary thyroid carcinoma identified regions potentially associated with a higher predisposition to lymph node metastasis.
|
24601688 |
2014 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the present work, a comparative genomic hybridization (CGH) study was performed using DNA from a primary tumor in a M918T RET mutation-positive SMTC patient and from its lymph node metastasis to investigate additional genetic alterations.
|
22676344 |
2012 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For each case, we sought RET somatic mutations in the primary cancer and in lymph node metastases.
|
21422198 |
2011 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Several cytoskeletal protein species showed quantitative changes in tumors and lymph node metastases harboring RET/PTC1 or RET/PTC3.
|
20839015 |
2011 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The closer mutations in codon 620, 618, and 611 were located to the transmembrane domain (codons 657-636) of the RET receptor, the greater were mean primary tumor diameters (23.5, 18.7, and 7.5 mm, P=0.020), the frequency of lymph node metastasis (75, 68, and 30%, P=0.11) and pheochromocytoma (38, 16, and 0%, P=0.11).
|
18936155 |
2009 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
More interestingly, the presence of a somatic RET mutation correlates with the presence of lymph node metastases at diagnosis, which is a known bad prognostic factor for the definitive cure of MTC patients.
|
18073307 |
2008 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RET/PTC rearrangements presented at younger age and had predominantly typical papillary histology, frequent psammoma bodies, and a high rate of lymph node metastases.
|
16434896 |
2006 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To our knowledge, this case represents the first documented case of concurrent lymph node metastases of MTC and PTC in a patient with RET proto-oncogene germline mutation.
|
14586073 |
2003 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tumors with ret/PTC gene rearrangements tended to have lymph node metastases rather than hematogenous spread.
|
10690905 |
2000 |
Secondary malignant neoplasm of lymph node
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis.
|
10675479 |
2000 |